SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-002888
Filing Date
2024-01-05
Accepted
2024-01-05 08:00:31
Documents
12
Period of Report
2024-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d103673d8k.htm   iXBRL 8-K 32545
  Complete submission text file 0001193125-24-002888.txt   153778

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA allo-20240103.xsd EX-101.SCH 2840
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20240103_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20240103_pre.xml EX-101.PRE 10805
6 EXTRACTED XBRL INSTANCE DOCUMENT d103673d8k_htm.xml XML 3245
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 24514465
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)